Search research articles
Contact Us
Filters
Showing results (261-270 of 282) with videos related to
Page
of 29
Sort By:
Kidney International
|
May 24, 2025
A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients
William R Mulley, Dhakshayini Tharmaraj, Kevan R Polkinghorne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Current Medical Research and Opinion
|
March 15, 2016
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
R Wuerstlein, K Sotlar, O Gluz, et al.
ESMO Open
|
March 25, 2023
Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study
M Li, S Mindt, A Lück, et al.
Breast (Edinburgh, Scotland)
|
July 22, 2017
Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study
Elisabeth Trapp, J Steidl, B Rack, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, B M Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
G von Minckwitz, M Rezai, P A Fasching, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
G von Minckwitz, M Rezai, H Tesch, et al.
Geburtshilfe Und Frauenheilkunde
|
August 1, 2017
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study
A Hein, B Rack, L Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 282) with videos related to
Sort By:
Page
of 29
Kidney International
|
May 24, 2025
A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients
William R Mulley, Dhakshayini Tharmaraj, Kevan R Polkinghorne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Current Medical Research and Opinion
|
March 15, 2016
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
R Wuerstlein, K Sotlar, O Gluz, et al.
ESMO Open
|
March 25, 2023
Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study
M Li, S Mindt, A Lück, et al.
Breast (Edinburgh, Scotland)
|
July 22, 2017
Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study
Elisabeth Trapp, J Steidl, B Rack, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, B M Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
G von Minckwitz, M Rezai, P A Fasching, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
G von Minckwitz, M Rezai, H Tesch, et al.
Geburtshilfe Und Frauenheilkunde
|
August 1, 2017
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study
A Hein, B Rack, L Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Page
of 29